Table 4.
Distribution of comorbidities presented by patients.
Age | Gender | 2020 |
2021 |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Comorbidity (n) |
Comorbidity (n) |
||||||||||||
None | dm | htn | asthma | DVT/PE | Ca | None | dm | htn | asthma | DVT/PE | Ca | ||
<20 | Male | - | - | - | - | - | - | 1 | - | - | - | - | - |
Female | 1 | - | - | - | - | - | 1 | - | - | - | - | - | |
20–29 | Male | - | - | - | - | - | - | 1 | - | - | - | - | - |
Female | 2 | - | - | - | - | - | 1 | - | - | - | - | - | |
30–39 | Male | 3 | - | - | - | - | - | 3 | - | 1 | - | - | - |
Female | 4 | - | - | - | - | - | 2 | - | 1 | - | - | 2 | |
40–49 | Male | 7 | - | - | - | - | - | 10 | 1 | 1 | - | - | - |
Female | 5 | - | - | - | - | - | 1 | - | - | - | 1 | - | |
50–59 | Male | 5 | 1 | 1 | - | - | 1 | 3 | - | - | - | - | - |
Female | 1 | - | - | - | - | - | 3 | - | - | - | - | - | |
60–69 | Male | 7 | 2 | 1 | 1 | - | - | 8 | 1 | 1 | - | - | - |
Female | 5 | - | - | - | - | - | 1 | - | - | - | - | - | |
70–79 | Male | 3 | - | - | - | - | - | 2 | - | - | - | - | - |
Female | 1 | - | - | - | - | - | 2 | - | 0 | - | 1 | - | |
80–89 |
Male | 1 | - | - | - | 1 | - | 1 | - | - | - | - | - |
Female | 0 | - | - | - | - | - | 1 | - | - | - | - | - | |
Total | 45 | 3 | 2 | 1 | 1 | 1 | 43 | 2 | 4 | 0 | 2 | 2 |
Key: dm = diabetes; htn = hypertension; DVT/PE = deep vein thrombosis/pulmonary embolism; Ca= Cancer.